Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 18/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4927298 | 0.91 | MCHR1 (0.59) | MCHR1KCNH2ALDH1A1MAPTHTT | |
| SCHEMBL4913438 | 0.80 | MCHR1 (0.64) | MCHR1KCNH2 | |
| SCHEMBL4922344 | 0.76 | MCHR1 (0.44) | MCHR1KCNH2ALDH1A1MAPTHTT | |
| SCHEMBL4925621 | 0.76 | MCHR1 (0.80) | MCHR1KCNH2 | |
| SCHEMBL4927397 | 0.76 | MCHR1 (0.60) | MCHR1KCNH2 | |
| SCHEMBL4922349 | 0.75 | MCHR1 (0.39) | MCHR1KCNH2ALDH1A1MAPTHTT | |
| SCHEMBL19263020 | 0.75 | SMN1; SMN2 (0.69) | ALDH1A1MAPTHTTCYP1A2SMN1; SMN2 | |
| SCHEMBL19263258 | 0.75 | HDAC1 (0.53) | ALDH1A1HTTCYP1A2SMN1; SMN2 | |
| SCHEMBL4923710 | 0.74 | KCNH2 (0.65) | MCHR1KCNH2ALDH1A1MAPT | |
| SCHEMBL4915122 | 0.74 | MCHR1 (0.63) | MCHR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306055-A1 | Heterocyclic Mchr1 Antagonists And Their Use In Therapy | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | claimed |
| EP-1831194-A1 | HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | claimed |
| WO-2006068594-A1 | HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | claimed |
| US-20080306055-A1 | Heterocyclic Mchr1 Antagonists And Their Use In Therapy | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| EP-1831194-A1 | HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006068594-A1 | HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306055-A1 | Heterocyclic Mchr1 Antagonists And Their Use In Therapy | MCHR1, MCHR2, MC1R | MCHR1 1/4885KCNH2 1440/4885ALDH1A1 2408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.